BiomeBank
BiomeBank is a clinical-stage biotechnology company dedicated to treating and preventing disease by restoring gut microbial ecology through innovative microbiome therapies. Utilizing a unique ecosystem-based approach and advanced co-culturing platform, Consortiome™, the company develops bespoke microbial therapies with targeted functions to address unmet medical needs globally. With a strong research background, regulatory achievements, and a state-of-the-art GMP manufacturing facility in Adelaide, BiomeBank aims to be a leader in microbiome-based medicine.
Industries
Nr. of Employees
small (1-50)
Products
Regulatory‑authorised donor-derived microbiome therapy (ARTG: 399066)
A donor-derived microbiome product authorised by a national regulator for restoration of gut microbiota, supplied in formulations for rectal/colonoscopic delivery with planned oral formats.
Cultured microbiome therapeutic candidate for ulcerative colitis (clinical-stage)
A rationally designed cultured microbial consortium derived from clinical human data intended to target ulcerative colitis, planned for early-phase clinical trials.
Cultured microbiome therapeutic candidate for an orphan indication (early-stage)
An early-stage cultured microbial therapy candidate developed using clinical and donor-derived data for a designated orphan disease indication.
Regulatory‑authorised donor-derived microbiome therapy (ARTG: 399066)
A donor-derived microbiome product authorised by a national regulator for restoration of gut microbiota, supplied in formulations for rectal/colonoscopic delivery with planned oral formats.
Cultured microbiome therapeutic candidate for ulcerative colitis (clinical-stage)
A rationally designed cultured microbial consortium derived from clinical human data intended to target ulcerative colitis, planned for early-phase clinical trials.
Cultured microbiome therapeutic candidate for an orphan indication (early-stage)
An early-stage cultured microbial therapy candidate developed using clinical and donor-derived data for a designated orphan disease indication.
Services
On-site cGMP production, quality control and distribution of live microbial therapy formulations for clinical use and clinical trials.
Collaborative development of rationally designed cultured microbial consortia using co-culturing platforms, data-driven strain selection and partner research programs.
End-to-end donor screening program and controlled processing pipeline to produce donor-derived microbiome material for clinical transplantation and use in approved indications.
On-site cGMP production, quality control and distribution of live microbial therapy formulations for clinical use and clinical trials.
Collaborative development of rationally designed cultured microbial consortia using co-culturing platforms, data-driven strain selection and partner research programs.
End-to-end donor screening program and controlled processing pipeline to produce donor-derived microbiome material for clinical transplantation and use in approved indications.
Expertise Areas
- Microbiome therapeutics development
- cGMP biomanufacturing of live biotherapeutics
- Co-culture bioprocessing and culturomics
- Clinical trial design and clinical supply
Key Technologies
- Co-culture bioreactor systems
- Hydrogel-supported culture platforms
- Anaerobic culturing and high-throughput isolation
- Large-scale microbial culture collections
News & Updates
BiomeBank received a multimillion-dollar grant from the Australian Government to develop a manufacturing facility for microbial therapeutics in Adelaide.
The company announced the opening of its new GMP manufacturing facility to increase supply of microbiome therapies.
Kolby Day was announced as the Chief Operating Officer to support growth and development.
BiomeBank’s donor-derived microbiome therapy, BIOMICTRA, received regulatory approval in Australia.
An article discussing BiomeBank's innovative microbiome therapies and market potential.
USA Today highlights BiomeBank as a leading startup shaping the future of microbiome medicine.
BiomeBank received a multimillion-dollar grant from the Australian Government to develop a manufacturing facility for microbial therapeutics in Adelaide.
The company announced the opening of its new GMP manufacturing facility to increase supply of microbiome therapies.
Kolby Day was announced as the Chief Operating Officer to support growth and development.
BiomeBank’s donor-derived microbiome therapy, BIOMICTRA, received regulatory approval in Australia.
An article discussing BiomeBank's innovative microbiome therapies and market potential.
USA Today highlights BiomeBank as a leading startup shaping the future of microbiome medicine.